Lorena Lorefice
Overview
Explore the profile of Lorena Lorefice including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
943
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Aprea M, Schiavetti I, Portaccio E, Ballerini C, Bonavita S, Buscarinu M, et al.
Mult Scler
. 2024 Mar;
30(6):707-713.
PMID: 38456445
Background: In the general population, maternal COVID-19 is associated with worse maternal and fetal outcomes. Two previous studies have assessed COVID-19 clinical outcomes in pregnant women with multiple sclerosis (MS),...
12.
Pau M, Arippa F, Leban B, Porta M, Casu G, Frau J, et al.
Bioengineering (Basel)
. 2024 Feb;
11(2).
PMID: 38391601
Together with the wide range of possible benefits for the rehabilitation/training of people with multiple sclerosis (pwMS) and other neurologic conditions, exposure to immersive virtual reality (VR) has often been...
13.
Lorefice L, Ferraro O, Fenu G, Amato M, Bresciamorra V, Conte A, et al.
J Neurol
. 2024 Jan;
271(4):1630-1637.
PMID: 38172380
Background: Generally infrequent, multiple sclerosis (MS) with late onset (LOMS) is characterized by an onset over the age of 50 and a mainly progressive course, while relapsing-remitting (RR) forms are...
14.
Di Filippo M, Ferraro D, Ragonese P, Prosperini L, Maniscalco G, Gallo A, et al.
J Neurol
. 2023 Nov;
271(1):24-31.
PMID: 37922069
Background: COVID-19 vaccines have been recommended to people with multiple sclerosis (pwMS) and, to ensure durable immunity, a third booster dose has been administered in several countries. Data about potential...
15.
Lorefice L, Fenu G, Fronza M, Murgia F, Frau J, Coghe G, et al.
Front Neurol
. 2023 Aug;
14:1251667.
PMID: 37602270
Background: Recent evidence has shown a significant association between menopause and multiple sclerosis (MS) progression. This study investigated the possible role of menopause in influencing MS from clinical and neuroradiological...
16.
Altieri M, Capuano R, Bisecco A, dAmbrosio A, Risi M, Cavalla P, et al.
Mult Scler Relat Disord
. 2023 Jul;
77:104870.
PMID: 37454568
Background: Covid-19 pandemic impacted on management of people with Multiple Sclerosis (pwMS). Level of satisfaction of pwMS regarding the care received by the staff of Multiple Sclerosis Centers (MSCs) during...
17.
Cocco C, Manca E, Corda G, Angioni M, Noli B, Congia M, et al.
Front Immunol
. 2023 Jun;
14:1157149.
PMID: 37383228
Introduction: The pathogenesis of neuropsychiatric systemic lupus erythematosus (NPSLE) is widely unknown, and the role of autoantibodies is still undetermined. Methods: To identify brain-reactive autoantibodies possibly related to NPSLE, immunofluorescence...
18.
Frau J, Coghe G, Lorefice L, Fenu G, Cocco E
Life (Basel)
. 2023 Jun;
13(6).
PMID: 37374092
Multiple sclerosis (MS), neuromyelitis optica (NMO) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD) are inflammatory diseases of the central nervous system (CNS) with a multifactorial aetiology. Environmental factors are important...
19.
Aprea M, Schiavetti I, Portaccio E, Ballerini C, Battaglia M, Bergamaschi R, et al.
Mult Scler
. 2023 May;
29(9):1090-1098.
PMID: 37232279
Background: In the general population, maternal SARS-CoV-2 infection during pregnancy is associated with worse maternal outcomes; however, only one study so far has evaluated COVID-19 clinical outcomes in pregnant and...
20.
Capuano R, Prosperini L, Altieri M, Lorefice L, Fantozzi R, Cavalla P, et al.
Mult Scler
. 2023 May;
29(7):856-865.
PMID: 37165941
Background: Little is known about COVID-19 course and outcomes after a third booster dose of mRNA vaccine against SARS-CoV-2 (mRNA-Vax) in patients with multiple sclerosis (pwMS) treated with ocrelizumab (OCR)...